Cost variation analysis of various brands of anti-retroviral agents currently available in Indian market: an economic perspective study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20221596Keywords:
Human immune deficiency virus, Anti-retroviral agents, Drug price control order, Pharmaco-economics, Cost variationAbstract
Background: The aim was to analyze the percentage cost variations among different brands of the commonly prescribed anti-retroviral agents in the treatment of human immunodeficiency virus.
Methods: The cost of different brands of commonly used Anti-Retroviral agents was sorted out by referring latest Indian drug index online, drug today, current index of medical specialties, Indian drug review.
Results: The percentage variation in the cost was above 100% with most of the commonly used anti-retroviral agents. Overall sequinafir 500 mg shows maximum cost variation of 1490.3%, while nelfinavir (625 mg) shows minimum cost variation of 6.1% in single drug therapy. Lamivudine 300 mg and tenofovir 300 mg combination shows maximum cost variation of 14055% whereas, lamivudine 150 mg, zidovudine 300 mg and efavirenz 600 mg shows minimum cost variation of 10% in combination drug therapy.
Conclusions: HIV is the most common infectious, life-threatening disease and drugs are to be prescribed for life-long period. If a costly brand is prescribed, the patients cannot afford to pay more money for their treatment. This also leads to poor patient compliance, dissatisfaction and failure of the treatment. Ideally, therefore, the drugs should be prescribed in such a way, to save the patient's economic burden and enhance the compliance of the treatment.
References
Goodman LS. In: Brunton L, Dandan R, Knollmann B, (ed.) Goodman and Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill; 2018:1137-55.
Yap PK, Loo Xin GL, Tan YY, Chellian J, Gupta G, Liew YK, et al. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention. J Pharm Pharmacol. 2019;71(9):1339-52.
Joshi RK, Mehendale SM. Determinants of consistently high HIV prevalence in Indian Districts: A multi-level analysis. PLoS One. 2019;14(5): e0216321.
Panchal SS, Pandit PR, Phatak AM, Lohi KM. Cost analysis of antiretroviral agents available in India. Int J Basic Clin Pharmacol. 2015;4(3):479-82.
Kumarasamy N, Krishnan S. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings. Current Opinion in HIV and AIDS. 2013;8(6):586-90.
Kumar GA, Dandona R, Rewari BB, Kumar SP, Tanwar S, Gagnier MC, et al. Decreasing cost of public sector first-line ART services in India from 2007-2008 to 2015-2016. Plos one. 2018;13(11): e0206988.
Raghav MV, Geetha A. Cost variation analysis of various brands of selective serotonin reuptake inhibitors currently available in the Indian market: An observational study. Natl J Physiol Pharmacy Pharmacol. 2022;12(3):263-6.
Kamath L, Satish GR. Cost variation analysis of antihypertensive drugs available in Indian market: an economic perspective. Int J Pharm Sci Res. 2016;7(5): 2050.
Ray A, Najmi A, Khandelwal G, Sadasivam B. A cost variation analysis of drugs available in the indian market for the management of thromboembolic disorders. Cureus. 2020;12(5):45-9.
Compendium of notified ceiling prices of scheduled drugs 2022 NPPA. Available at: Error! Hyperlink reference not valid.. Accessed on 25 November 2021.
Moreno S, Perno CF, Mallon PW, Behrens G, Corbeau P, Routy JP, et al. Two-drug vs. three-drug combinations for HIV-1: do we have enough data to make the switch?. HIV Med. 2019;20:2-12.
